Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d17db0d56f38da38b9228be24eaaec17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0fcbc9ca53bc68f405f71764197469b5 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57 |
filingDate |
2007-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16da67ec7c65819d5e49a3c4324b509e |
publicationDate |
2007-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2007131041-A2 |
titleOfInvention |
The use of a glucocorticoid receptor ii antagonist to treat depression in patients taking il-2 |
abstract |
The invention pertains to the discovery that type II glucocorticoid receptor antagonists can be used in methods for reversing or inhibiting the symptoms of depression in patients receiving interleukin-2 treatment. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8901310-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9829495-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8445520-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10006924-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7547714-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010517991-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10495650-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11073523-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7786097-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7598231-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8158660-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115053861-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017027851-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017123633-A1 |
priorityDate |
2006-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |